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Synopsis 
Proteolysis Targeting Chimeras (PROTACs) can be used to precisely target a subunit of a 
transcriptional complex for degradation in subpopulations of cells. 
  
 
 
 
 
.CC-BY-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/595389doi: bioRxiv preprint first posted online Apr. 2, 2019; 
2 | Yu et al.  
Abstract 
Immunomodulators (IMiDs) are an effective class of drugs used to treat blood cancers. 
IMiDs are believed to work by recruiting protein targets containing a -hairpin motif for 
ubiquitination by E3 ubiquitin ligase complexes composed of cereblon (CRBN), Cullin-4a 
(CUL4a), DNA Damage Binding protein-1 (DDB1), and Ring Box-1 (RBX1). The 
ubiquitinated protein is subsequently degraded by the proteasome. By characterizing the 
repertoire of proteins that show an increased physical association with CRBN after IMiD 
treatment, we identified a novel IMiD substrate, Widely Interspaced Zinc Finger Motifs 
(WIZ). WIZ contains a C2H2 zinc finger domain, like several other substrates that were 
previously characterized. We demonstrate that IMiDs stabilize physical association of 
WIZ with CRBN, deplete WIZ steady state protein levels in a way that is dependent on E3 
ligase activity, and enhance the rate of its degradation. Notably, proteins that assemble 
with WIZ are co-recruited to CRBN by IMiDs but are not degraded, illustrating the potential 
of targeted protein degradation to eliminate individual subunits of a protein complex. 
These findings suggest that systematic characterization of the full repertoire of proteins 
that are targeted for degradation by IMiD compounds will be required to better understand 
their biological effects. 
IMiD 1 | Cereblon 2 | PROTAC 3 | ... 
Introduction 
Redirecting the existing cellular degradation machinery to remove unwanted components rapidly 
and specifically is potentially a versatile therapeutic approach (1) . One possible strategy to 
achieve this goal is to redirect the proteasome, a large enzyme that digests proteins. Selective 
elimination of one subunit of a multi-protein complex by this approach is possible because the 
proteasome can extract a single subunit from a complex, unfold it, and thread it into its inner 
chamber, where the protease active sites reside (2). Therefore, what is needed is a mechanism 
to redirect the proteasome to remove a therapeutic target in addition to its endogenous 
substrates. 
The proteasome normally identifies and enriches for proteins that need to be removed by using 
ubiquitin as an affinity tag (3, 4). Ubiquitin is an 8 kDa protein that is ubiquitously expressed in 
eukaryotic organisms (5). The C-terminal glycine on ubiquitin is conjugated to the amine on 
lysines of the target proteins via an isopeptide linkage. Formation of an ubiquitin polymer with at 
least 4 monomeric units yields a signal that binds tightly to the proteasome (6, 7). Therefore, one 
way to degrade an intracellular therapeutic target would be to catalyze the ubiquitination of the 
target to redirect it to the proteasome. 
Three enzymes act in tandem to catalyze selective ubiquitination of proteins (8, 9). E1 first 
converts the C-terminal carboxylic acid on ubiquitin into a more reactive thioester to enhance 
the rate of reaction, as the C-terminus of ubiquitin is fairly chemically inert. The activated ubiquitin 
is transferred as a thioester to an E2, and the E2 ubiquitin thioester then binds to an E3 enzyme, 
.CC-BY-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/595389doi: bioRxiv preprint first posted online Apr. 2, 2019; 
Yu et al.   
which also binds to substrate. RING-type E3 enzymes position the E2 for subsequent transfer 
of ubiquitin to a lysine residue on the bound substrate (10) . Since E3 ubiquitin ligases are the 
components of this pathway that identify which proteins get ubiquitinated, one strategy to redirect 
the proteasome to digest a therapeutic target is to modify the substrate specificity of an E3 
ubiquitin ligase to recognize the protein of interest. 
One class of E3 ubiquitin ligases that have been successfully redirected towards a therapeutic 
target (i.e. neosubstrate) are cullin-RING type E3 ubiquitin ligases (CRLs) (11-21). A 
distinguishing feature of CRLs is that they contain interchangeable subunits that recruit specific 
substrates to the enzymatic core (10). CRLs work by catalyzing the discharge of ubiquitin from 
E2 onto a lysine residue of a juxtaposed natural or neosubstrate.  
 
Fig. 1. Mechanism of action for IMiDs. (a) CRBN is normally in complex with DDB1, which in 
turn interacts with CUL4-RBX1 to form the ubiquitin ligase CRL4CRBN (22, 23). IMiDs nucleate a 
novel protein-protein interaction between CRBN and a cellular protein (neo-substrate) (14, 20, 
21). Ubiquitin-thioesterified to an ubiquitin conjugating enzyme (E2) is recruited to CRL4CRBN by 
RBX1, which brings activated ubiquitin into proximity of the neosubstrate (10). (b) General 
structure of IMiDs. Addition of the blue NH2 group to thalidomide yields lenalidomide. Removal 
of the red carbonyl group from lenalidomide yields pomalidomide. 
 
Investigating molecules that work by re-directing CRL activity toward neosubstrates can inform 
the design of future drugs. One class of drugs that redirect CRL activity towards neosubstrates 
is referred to as IMiDs, or immunomodulatory drugs (24). IMiDs have been shown to be effective 
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for the treatment of hematological malignancies by redirecting cereblon (CRBN), the 
interchangeable substrate receptor that determines the specificity of the CRL4CRBN complex, to 
recruit a set of neosubstrates (Fig.1a) (14, 20, 21, 25). CRBN is one of many substrate receptors 
that are recruited to CUL4-RBX1 by DDB1 to form CRL4 complexes (Fig.1a) (22, 23). 
IMiDs are bipartate molecules that act as a molecular bridge to link neosubstrates to CRBN. The 
glutarimide moiety binds CRBN, and the phthalimide moiety binds to protein targets (Fig.1b) (26, 
27). All known IMiD-dependent neosubstrates reported for CRL4CRBN are predicted to contain a 
β-hairpin motif, like Casein Kinase 1α (CK1α) and the C2H2 zinc finger proteins Ikaros (IKZF1), 
ZFP91, Sal-like protein 4 (SALL4) and Aiolos (IKZF3) (Fig.1a) (14, 20, 21, 25, 28, 29). Crystal 
structures have shown that the β-hairpin motif comes into contact with the phthalimide moiety of 
IMiDs bound to CRBN, which explains how these drugs work (30, 31). 
Because novel substrates are recruited to CRBN through the phthalimide moiety of IMiDs, 
understanding how modification of the basic bicyclic IMiD scaffold influences the identity of the 
neosubstrates that are recruited to CRBN will be critical for the development of new analogs with 
different patterns of selectivity (Fig.1b). Interestingly, relatively modest alterations to the IMiD 
scaffold can have surprisingly dramatic effects. For example, substitution of an amine at the 4’ 
position of thalidomide (Fig.1b) (as occurs in lenalidomide and pomalidomide) results in a 100 
to 1,000-fold increase in potency (32). Another dramatic example of specificity is seen with 
deletion of a simple carbonyl from pomalidomide to generate lenalidomide (Fig.1b), which 
enables targeting of the neosubstrate CK1α for ubiquitination and degradation (25, 30). Thus, 
relatively subtle modifications to the IMiD chemical scaffold result in dramatic changes in its 
biological properties. Additionally, it remains unknown how the effects of IMiDs are modified in 
different cell types. If we are to understand how to harness targeted protein degradation, it will 
be important to understand the physical and chemical basis for targeting by identifying and 
characterizing specific neosubstrates. 
Results 
IMiDs enhance physical association of CRBN with proteins with Zinc Finger domains 
Previous IMiD substrates have been identified in proteomics experiments by determining which 
proteins accumulate as ubiquitinated intermediates or exhibit a shorter half-life in the presence 
of IMiDs (19, 21, 25, 28, 29). However, there are several disadvantages to both of these 
methods. First, ubiquitinated intermediates typically account for a tiny fraction of the total protein, 
and only a tiny fraction of all peptides from a protein have ubiquitin conjugated to them (33). 
Second, the rate of decay is nonlinear, and the half-life of proteins can range from minutes to 
months (34), potentially confounding a large-scale screen analyzed at a single time point. 
To circumvent these issues, we chose to identify proteins whose physical association with CRBN 
was enhanced upon treatment with lenalidomide, as we reasoned that this was the most direct 
and sensitive method. To accomplish this, we used a THP-1 cell line that was transiently 
transfected to express FLAG-CRBN (Fig.2a). 
.CC-BY-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/595389doi: bioRxiv preprint first posted online Apr. 2, 2019; 
Yu et al.   
 
Fig. 2. Proteins with Zinc Finger Domains show enhanced physical association with CRBN in 
the presence of lenalidomide. (a) Outline of IP-MS strategy to identify proteins that show an 
enhanced physical association. (b) Peptide count of proteins identified in the experiment. This 
includes those known to bind CRBN, known core components of the CRL4CRBN complex, zinc 
finger proteins, and novel binding partners. 
 
We identified candidate proteins by treating cells with or without lenalidomide for 2 hours, 
immunoprecipitating for CRBN via the FLAG epitope, and identifying which proteins showed 
enhanced physical association with CRBN in the presence of lenalidomide via quantitative 
shotgun mass spectrometry (Fig.2a). Components of the enzymatic core of CRL4CRBN (CUL4a 
and RBX1) and the adapter (DDB1) that scaffolds CRBN’s interaction with the enzymatic core 
were recovered in equal amounts regardless of the presence or absence of lenalidomide 
(Fig.2b). 
Previously characterized neosubstrates (ZFP91, IKZF1, IKZF3, and CK1α) showed IMiD-
dependent association, validating this approach (Fig.2b) (14, 20, 21, 25, 28). However, one 
limitation of this approach is that enhanced physical association with CRBN might not 
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necessarily result in a productive degradation event (35).  
Levels of transcriptional complex member WIZ are reduced upon IMiD treatment 
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Fig. 3. WIZ protein abundance shows IMiD dependent regulation. L363 cells were maintained 
in RPMI-1640 with 10% FBS and 2 mM glutamine before treatment with (a) pomalidomide, (b) 
lenalidomide, or (c) thalidomide for 12 hours at 0, 1, or 10 µM. Cell lysates prepared from 
triplicate cultures were processed for SDS-PAGE and immunoblotting with antibodies to the 
indicated proteins and the signals were quantified on a LICOR Odyssey. The median level of 
each protein normalized to no drug is shown below the immunoblot image for each set of 
triplicates. All protein levels were normalized to GAPDH, which served as a loading control. The 
previously identified substrates ZFP91, IKZF1, and CK1α serve as positive controls (14, 20, 21, 
25, 28). PATZ1, ZFP684, and ZNF644 were the other zinc finger proteins screened. 
 
To investigate how many of the IMiD-dependent binding events translated into productive 
degradation, we examined by immunoblotting a subset of the identified proteins to see if their 
steady state levels dropped after IMiD treatment (Fig.3a–c). We selected proteins with a zinc 
finger domain, because multiple previously characterized IMiD-dependent substrates (e.g. 
IKZF1, IKZF3, ZFP91, SALL4, ZFP692) are zinc finger proteins (14, 20, 21, 25, 28, 29). L363 
cells were treated with pomalidomide, lenalidomide, or thalidomide for 12 hours at multiple doses 
(0, 1, and 10 µM), in biological triplicate (Fig.3a–c). Both isoforms of WIZ (the identity of the 
isoforms was confirmed by knockdown; Fig. S1) showed the largest fold change after treatment 
with pomalidomide (Fig.3a). Previously characterized substrates (e.g. IKZF1) showed IMiD 
dependent depletion (Fig.3a–c). Additionally, CK1α exhibited lenalidomide selective depletion, 
(Fig.3b) as had been reported previously (25). 
IMiD regulation shows cell type dependence 
 
 
 
Fig. 4. IMiD regulation of WIZ is cell type specific. THP-1 Cells were then treated with (a) 
pomalidomide or (b) lenalidomide at 0, 1, or 10 µM. for 12, 24, 36, and 48 hours. Cell lysates 
were separated by SDS PAGE, and immunoblotted against antibodies for WIZ, CRBN, IKZF1, 
CK1α, and GAPDH. 
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To understand how generalizable IMiD-dependent depletion of WIZ was across different cell 
types, THP-1 cells were treated with pomalidomide and lenalidomide (0, 1, and 10 µM) for 12, 
24, 36, and 48 hours and protein levels were evaluated by immunoblotting (Fig.4a–b). Previously 
characterized IMiD dependent substrates like IKZF1 (14, 20, 25) served as a positive control.  
Unlike what we observed in L363 cells (Fig.3a), no reduction of WIZ was observed in THP-1 
cells (Fig.4a-b), whereas IKZF1 was depleted in both cell types (Figs.4a-b and 3a-c). Previous 
work had indicated that WIZ was downregulated in H9 hESC (29). Thus, the IMiD effect on WIZ 
shows cell type dependence.  
WIZ binding partners are not regulated by IMiD 
 
 
 
Fig. 5. IMiDs regulate the abundance of WIZ, but not the other components of the complex. 
MM.1s cells were treated in triplicate for 24 hours with (a) pomalidomide or (b) lenalidomide at 
0, 1, or 10 µM. Cell lysates were separated by SDS PAGE and immunoblotted with antibodies 
against WIZ, EHMT1, EHMT2, and ZNF644. Immunoblot signals were quantified on a LICOR 
Odyssey. The mean level of each protein normalized to no drug and to the GAPDH signal in the 
same samples is shown below the immunoblot image for each set of triplicates. 
 
WIZ is a protein that is normally in a transcriptional complex with EHMT1, EHMT2, and ZNF644 
(36, 37). It is believed to target methyltransferases to specific DNA sequences via its zinc finger 
motif. Our mass spec data revealed the entire complex was recruited to CRBN after treatment 
with IMiD (Fig.2b). To tease out if WIZ was the only component of the transcriptional complex 
that showed regulation, MM.1s cells were treated with lenalidomide or pomalidomide (0, 1, or 10 
µM) for 24 hours, and WIZ, EHMT1, EHMT2, and ZNF644 were evaluated by immunoblotting 
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(Fig.5a–b). Depletion of both WIZ and the validated substrate IKZF1 were observed, but the 
other components of the WIZ transcriptional complex remained stable. 
Levels of WIZ are specifically modulated by IMiDs with an amine modification at the 4’ 
position 
 
 
 
Fig. 6. WIZ protein abundance is specific to IMiDs modified with an amine at the 4’ position. (a-
c) MM.1s or (d) MM.1s cells with CRBN knocked down with an shRNA were treated with (a) 
lenalidomide, (b) (d) pomalidomide, or (c) thalidomide at 0, 1, or 10 µM for 12- 48 hours. Cell 
lysates were separated by SDS PAGE and immunoblotted against antibodies for WIZ, CRBN, 
IKZF1, CK1α, and GAPDH. 
 
To elucidate how subtle modifications in the IMiD scaffold influenced WIZ depletion, MM.1S cells 
were treated with pomalidomide, lenalidomide, or thalidomide (0, 1, and 10 µM) for 12, 24, 36, 
and 48 hours (Fig.6a–c). Both isoforms of WIZ showed the largest fold change upon treatment 
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with IMiDs with an amine in the 4’ position (lenalidomide and pomalidomide), with pomalidomide 
showing the strongest effect (Fig.6a-b). 
 
IMiD dependent depletion of WIZ is dependent on CRL4CRBN’s E3 ubiquitin ligase activity 
 
 
Fig. 7. IMiD induced degradation of WIZ is dependent on E3 ubiquitin ligase activity and 
proteasome degradation. L363 cells were maintained in RPMI-1640 with 10% FBS before 
treatment with pomalidomide at 0, 1, or 10 µM in biological triplicate. They were cotreated with 
either (a) DMSO, (b) the proteasome inhibitor bortezomib, or (c) the Nedd8 conjugation inhibitor 
pevonedistat (38, 39).  Cell lysates were separated by SDS-PAGE and immunoblotted against 
the indicated antibodies.  NRF1 was used as a positive control for the proteasome inhibitor (40). 
IKZF1 was a positive control for IMiD treatment. GAPDH was the loading control. The action of 
pevonedistat was confirmed by its effect on CUL4 neddylation. 
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IMiDs enhanced the physical association between WIZ and CRBN, resulting in the depletion of 
WIZ which is consistent with the hypothesis that WIZ is a new CRL4CRBN neosubstrate. We next 
sought to directly test this hypothesis. Depletion of CRBN in MM.1s cells strongly blocked 
pomalidomide-induced depletion of WIZ (Fig. 6b, d), confirming that CRBN was indeed required 
for the effect. To address the role of CRL E3 activity and the proteasome, L363 cells were treated 
with 0, 1, or 10 µM of pomalidomide for 12 hours in the absence or presence of the Nedd8 
conjugation inhibitor pevonedistat or the proteasome inhibitor bortezomib (Fig.7a–c) (38, 39).  
IMiD depletion of WIZ and known substrates such as IKZF1 was blocked upon cotreatment with 
proteasome inhibitor, indicating the effect was dependent on proteasome activity (Fig.7a, b). 
Nedd8 is an ubiquitin-like protein that activates CRLs upon its conjugation to the cullin subunit 
(41). Co-treatment with 250 nM pevonedistat caused accumulation of CUL4 in the de-neddylated 
state, indicating that the enzymatic core of the complex was catalytically inactive (Fig.7a, c). 
IMiD depletion of WIZ and IKZF1 was also blunted by pevonedistat, indicating that the effect was 
dependent upon the core complex being enzymatically active (Fig.7a, c). 
IMiD dependent depletion of WIZ protein levels was due to enhancing the rate of decay 
 
 
 
Fig. 8. Pomalidomide stimulates the degradation of WIZ, but not other components of the 
complex. MM.1s cells were maintained in RPMI-1640 before treatment with cycloheximide (150 
µg/mL) (a) without or (b) with 10 µM of pomalidomide. Cells were harvested at 0, 2, 4, 6, 8, 12, 
and 14 hours, lysed, and separated by SDS-PAGE and immunoblotted for WIZ, IKZF1, EHMT1, 
EHMT2, and GAPDH.  
 
Although we found IMiD dependent depletion of WIZ required both CRBN and CRL ubiquitin 
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ligase activity (Figs.6b, d and 7a–c), it could be due to increased degradation of WIZ or inhibition 
of WIZ expression. To decouple these two possible outcomes, we compared the rate of decay 
by treating cells with or without IMiD in the presence of an inhibitor of translation (Fig.8a-c) (42). 
We saw that both isoforms of WIZ, as well as IKZF1 experienced a higher rate of decay upon 
addition of IMiD (Fig.8b-c), consistent with this being due to an increased rate of degradation. 
We saw that IKZF1 and both isoforms of WIZ, but not EHMT1 and EHMT2, exhibited an 
increased rate of decay upon addition of IMiD (Fig.8b-c), consistent with this being due to an 
increased rate of degradation targeting only one subunit.  
Discussion 
Targeted protein degradation is rapidly becoming an area of intense interest for the 
biopharmaceutical industry (43). The overall goal for researchers in this area is to design a drug 
that selectively targets a particular protein of interest for ubiquitin-dependent degradation via the 
proteasome. One particular class of drugs, the IMiDs, achieves its effects through selective 
destruction of specific neosubstrates via the CRL4CRBN ubiquitin ligase pathway (14, 20, 21). 
Interestingly, IMiDs that differ from each other in subtle ways elicit the degradation of different 
sets of overlapping neosubstrates. To better understand the biological effects of IMiDs and to 
gain insight into the mechanisms by which IMiDs recruit substrates to CRBN, we employed an 
affinity purification-mass spectrometry approach to identify proteins that bound CRBN in an IMiD-
dependent manner. This led to the identification of a dozen proteins, including the previously-
described CRL4CRBN neosubstrates IKZF1, IKZF3, ZFP91, ZNF692 and CK1α (14, 20, 21, 25, 
28). In addition, we identified a number of zinc finger proteins, including WIZ. Note that while this 
work was being prepared for submission, Thomä and colleagues reported the interaction of a 
large collection of zinc fingers proteins with CRBN, including those reported here (44). 
We show here that WIZ is a bona-fide neosubstrate for CRL4CRBN. In addition to increasing 
association of WIZ with CRBN, IMiDs also induced depletion of WIZ that was dependent on the 
CRBN protein, CRL activity (as determined with the pan-CRL inhibitor pevonedistat), and 
proteasome activity. Importantly, depletion of WIZ was due to an increase in its rate of 
degradation. The effect of IMiDs on WIZ degradation was selective, in that only IMiDs with an 
amino group at the 4’ position (lenalidomide and pomalidomide) induced degradation, with 
pomalidomide showing substantially stronger activity. This is consistent with prior observations 
that subtle differences in IMiD structure can have powerful discriminating effects on substrates 
such as CK1α (25, 30). In addition, we observed IMiD-dependent depletion of WIZ in L363 but 
not in THP-1 cells. We do not know the reason for this selectivity. However, it is not due to the 
inability of WIZ to bind transfected CRBN in an IMiD-dependent manner in these cells (e.g. see 
Fig.2b) and it is not due to absence of CRL4CRBN activity in THP-1 cells because IKZF1 was 
efficiently downregulated by IMiDs in these cells. This selectivity points to the potential to develop 
therapeutic agents that induce degradation of target proteins in a cell type specific manner. 
Our data, combined with other recently reported results, raise the question of whether the effects 
of IMiDs in vivo are more complex than originally envisioned, and could potentially be influenced 
by depletion of multiple proteins in addition to the original neosubstrates IKZF1, IKZF3, and 
CK1 (14, 20, 21, 25). A great deal of effort is being invested in developing proteolysis-targeting 
chimeric molecules (PROTACs) that, like IMiDs, induce the degradation of specific proteins to 
achieve a therapeutic effect (43, 45). A result we observed here that is of particular relevance to 
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those efforts is that IMiD induced depletion is highly selective for a single subunit of a 
multisubunit complex. WIZ associates with EHMT1, EHMT2, and ZNF644 to form a gene 
regulatory complex (36, 37), and all four of these proteins were recruited to CRBN in the 
presence of IMiD. However, only WIZ was degraded. This is consistent with the previously 
observed subunit selectivity of the ubiquitin proteasome pathway both in vivo and in reconstituted 
systems (46, 47). Harnessing the power of subunit-selective degradation to remodel cellular 
machines to achieve a highly selective therapeutic outcome holds promise for the development 
of a suite of next-generation medicines. 
 
Experimental Procedures 
A. Materials. Bortezomib (B-1408) was purchased from LC Laboratories. Pomalidomide 
(P0018-25MG) and N-ethyl maleimide (E3876-5G) were purchased from Sigma Aldrich. 
Lenalidomide (HY-A0003) and pevonedistat (905579-51-3) were purchased from MedChem 
Express. All were prepared as single-use DMSO stocks and stored at -20o C before usage. 
Laemmli Buffer (1610737) was purchased from Biorad. BSA (9998S) was purchased from Cell 
Signaling Technology. 
B. Antibodies. GAPDH (SC-365062) antibody was from Santa Cruz Biotechnology. CUL4a 
(2699S), DDB1 (A300-462A), EHMT1 (A301-642A-M), and ZNF644 (A301-642a-M) antibodies 
were from Bethyl Laboratories. CRBN (HPA045910) and FLAG (F1804) antibodies were from 
Sigma Aldrich. WIZ (ab92334), ZNF521 (ab156271), CK1α (ab108296), and EHMT1 (ab185050) 
antibodies were from Abcam. PATZ1 (PA5-30478), ZNF684 (PA5-40984), and ZFP91 (PA5-
43064) antibodies were from Thermo Fischer Scientific. Anti-Rabbit IgG IR800 (926-32211) was 
purchased from Li-COR Biosciences. Anti-Mouse IgG IR680 (A10038) was purchased from 
Invitrogen.  
C. Cell lines. MM.1s and THP-1 cells were purchased from ATCC. L363 cells were provided by 
Francesco Parlati, Calithera Biosciences, South San Francisco. Cells were grown in RPMI-1640 
(ATCC formulation), with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, and 
penicillin-streptomycin. THP-1 cells were supplemented with 50 µM β-mercaptoethanol. Cell 
lines were tested for mycoplasma using Lonza’s MycoAlert Mycoplasma Detection kit and 
authenticated by Laragen using PowerPlex 16 system, as well as the Cell Line ID.  
D. Western blot analysis. MM.1s, THP-1, or L363 cells for each sample, as well as a replicate 
to measure protein levels were harvested by centrifugation and resuspended in pre-warmed 
RPMI-1640 at 1 million cells/mL. They were then seeded onto 24 well plates, in 1.5 mL total 
volume. Pomalidomide was added from a 1000x stock. Cell pellets were collected by 
centrifugation and flash frozen for processing later. A separate replicate to normalize protein 
concentration was washed twice with PBS before being flash frozen. Samples were then 
solubilized in 200 µL of Laemmle buffer supplemented with fresh β-mercaptoethanol and 
protease inhibitor cocktail. Cell lysates were sonicated (5 s; 10%) and cleared by centrifugation 
before boiling for 3 minutes. Boiled lysates were cleared by centrifugation (14,000 xg). Relative 
protein concentrations were calculated based on samples lysed in 2% SDS in the BCA assays, 
and the total lysate volume was adjusted according to that. Samples were loaded onto 4–12% 
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protein gels. Following electrophoresis, gels were transferred to nitrocellulose for 3 hours at 70 
V, with stirring. 
E. RNAi-mediated knockdown. siRNAs were purchased from Santa Cruz Biotechnology. Cells 
were seeded at a final concentration of 500,000/mL (THP-1 cells), and transfected with Opti-
MEM and Lipofectamine RNAimax, as previously described. Cells were harvested after 48 and 
72 hours and analyzed for efficiency of knockdown. 
F. Cycloheximide Chase. MM.1s cells were seeded at 106 cells/mL in complete RPMI-1640 
with 10% FBS in 24 well plates. Cells were treated with 0 or 10 µM pomalidomide, along with 
150 µg/mL of cycloheximide to initiate the chase. Cells were harvested at the indicated times 
and subjected to immunoblot analysis. 
G. Mass Spectrometric sample preparation. Eluted samples were reduced in 3 mM TCEP for 
20 min. Reduced samples were alkylated with 10 mM NEM for 30 min at room temperature in 
the dark. Reduced and alkylated samples were digested with Lys-C (Wako) at a 1:200 ratio for 
4 hours at room temperature. Partially digested lysates spiked with 1 mM CaCl2 were diluted 
with 50 mM Tris (pH 8.0) down to 2 M urea before being digested with sequence grade trypsin 
(Promega) diluted 1:100, at 37°C overnight in the dark. The reaction was quenched after 15 
hours by adding trifluoroacetic acid (TFA) to 0.1%. Lysates were cleared via centrifugation at 
4000xg for 15 minutes. Peptides were desalted using a 500 mg capacity Sep-Pak column that 
was prehydrated with 7 column volumes of acetonitrile (21 mL), followed by an equilibration step 
with 7 column volumes of Buffer A (0.1% TFA in H2O) (21 mL). Cleared peptides were loaded 
onto the resin by gravity flow, washed with 7 column volumes of Buffer A, followed by 3 column 
volumes of Wash Buffer (0.1% TFA, 5% acetonitrile in H2O). Desalted peptides were eluted with 
2 column volumes of Elution Buffer (0.1% TFA, 40% acetonitrile in H2O) (6 mL). The resulting 
peptide sample was frozen by storing at 80°C for at least 1 hour and dried via lyophilization. 
H. NanoLC-MS/MS analysis. The dried immunoprecipitated peptides were resuspend 0.2% 
formic acid, 2% acetonitrile, nanoLC grade 97.8% H2O and subjected to proteomic analysis 
using an EASY 1000 nano-UPLC (Thermo Fisher Scientific) connected on-line to an Orbitrap 
Fusion mass spectrometer with a nanoelectrospray ion source (NanoFlex, Thermo Scientific). 
Peptides were separated with a 120 min gradient using a 15 cm silica analytical column with a 
75 µm inner diameter packed in-house with reversed phase ReproSil-Pur C18AQ 3 µm resin 
(Dr. Maisch GmbH, Amerbuch-Entringen, Germany). The flow rate was set to 350 nl/min, and 
the gradient was as follows: 2-6% (7.5 min), 6-25% (82.5 min), 25-40%(30 min), 40-100% (1 
min) B (0.2% formic acid, 80% acetonitrile, 19.8% nanoLC grade H2O). The mass spectrometer 
was set to collect data in a data-dependent (top speed) mode, switching automatically between 
full-scan MS and tandem MS acquisition. Samples were analyzed by Higher Collision Energy 
(HCD) fragmentation. 
I. Data Analysis. Raw data was searched using MaxQuant (48, 49), version 1.6.5.0. Precursor 
mass tolerance was set to 4.5 ppm after recalibration and fragment tolerance was 0.5 Da. 
Oxidation of methionine and protein N-terminal acetylation were specified as variable 
modifications and carbamidomethylation of cysteine was specified as a fixed modification. 
Trypsin was specified as the digestion enzyme, with up to two missed cleavages allowed. 
Spectra were searched against the UniProt human database (93591 entries) and a contaminant 
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database (246 entries). Score thresholds were established so that peptide and protein false 
discovery rates were less than 1% as estimated by a target-decoy approach. Match between 
runs and iBAQ quantitation (50) were enabled. iBAQ parts per million (ppm) abundances were 
calculated by multiplying individual protein iBAQ abundances by 106 and dividing by the sum of 
all non-contaminant protein iBAQ values. 
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